tirzepatide cvot SURPASS-CVOT: Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D TIRZEPATIDE (COAGONISTA GIP/GP1): DESARROLLO CLINICO
Description
The Lancet , 398 (10314), 1807-1817
If it's above 7 you're adjusting well
Instead of cutting her calories until she felt starved and drained, we gave her a macro based plan with enough food to fuel training and rebuild lean muscle
Le traitement demande donc une routine claire
While both drugs can be effective in their own right, they can influence each others effectiveness and possibly cause side effects when used together
Nastpnie, po co najmniej 4 tygodniach przyjmowania dawki 0,5 mg raz na tydzie, dawk mona zwikszy do 1 mg raz na tydzie w celu dodatkowej poprawy kontroli glikemii
